Page 3 - Drug Pricing Program News Today

A battle between the Arkansas Insurance Department and pharmaceutical manufacturers is heating up with the announcement of a hearing this summer to consider administrative penalties against AstraZeneca Pharmaceuticals LP, the drug manufacturing giant that filed a lawsuit against the state earlier this year over Act 1103 of 2021 -- the 340B Drug Pricing Nondiscrimination Act.

I’m a patient who, like many other patients, is sharing my story of how 340B benefitted me.

The 340B Drug Pricing Program was intended to help our most vulnerable citizens access medicines and care when they are sick

The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.

Performance Reflects Execution and Actions to Strengthen the Companys Long-Term Growth Profile First Quarter Revenues were $11.9 Billion, increasing 5% Growth Portfolio Revenues were $4.8...

IntheU.S.,severalkeylegislationshaveaprofoundimpactongovernmentpricingofdrugs,especiallywithinpublichealthprogramslikeMedicare...

Healthcare

On April 1, 2024, the Centers for Medicare & Medicaid Services (CMS) released the Announcement of Calendar Year (CY) 2025 Medicare Advantage (MA) Capitation Rates and Part C and Part D...

Guest Commentary: States are pushing back against attempts by drug companies to roll back a discount program “safety net” health providers use to care for vulnerable, low-income Americans.

In recent years, drug manufacturers have declined to offer 340B discounts on their covered outpatient drugs, creating disruption for the patients who rely on them